HIIT vs. Resistance: Which Crushes Cancer Cells?

A woman in athletic wear holding her chest with a pained expression outdoors

One brutal 45-minute workout unleashes your muscles’ hidden arsenal against breast cancer cells, slashing their growth by up to 29%—but which style packs the bigger punch?

Story Highlights

A single session of resistance training or HIIT boosts anti-cancer myokines like IL-6 and decorin in breast cancer survivors.
Post-exercise blood from survivors suppressed aggressive MDA-MB-231 cancer cell growth by 19-29% in lab tests.
HIIT edged out resistance training in immediate IL-6 surge and cell suppression, with p=0.001 significance.
Study at Edith Cowan University involved 32 stage I-III survivors, average age 59, marking the first direct RT vs. HIIT comparison.
Exercise mimics drug-like effects, offering low-cost, accessible anti-cancer benefits without pharma intervention.

Study Design and Participant Profile

Researchers at Edith Cowan University in Australia randomized 32 breast cancer survivors, stages I-III with average age 59, into resistance training or HIIT groups. Francesco Bettariga, PhD candidate, led the trial embedded in a 12-week program. They collected blood pre-exercise, immediately post, and 30 minutes post from single 45-minute bouts repeated three times weekly. Resistance training used chest press, leg press, and lunges. HIIT delivered seven high-intensity bursts.

Myokine Surge After One Session

Both workouts spiked serum levels of anti-cancer myokines: decorin, IL-6, SPARC, and OSM. These muscle-secreted proteins fight tumor growth. HIIT triggered a 47% IL-6 elevation immediately post-exercise, outpacing resistance training. Authors link HIIT’s edge to greater muscle activation and metabolic stress, plus catecholamines. Applied to MDA-MB-231 cells—an aggressive triple-negative subtype—post-exercise blood curbed growth 19-29%.

HIIT Edges Resistance in Immediate Suppression

HIIT suppressed cancer cell growth more potently right after exercise, achieving 19-29% reduction versus resistance training’s 20-21%. Statistical significance hit p=0.001 for HIIT’s superiority. Over 12 weeks, no major differences emerged in myokine release or chronic effects, but HIIT yielded better lean mass gains. This first head-to-head trial proves single bouts mimic pharmaceutical anti-cancer action.

Exercise oncology traces to data showing physical activity cuts breast cancer risk 20-30% and boosts survival. Myokines emerged in the 2010s as mediators; prior lab work confirmed they inhibit proliferation, but lacked acute RT-HIIT comparisons. Chronic trials hinted at benefits, yet this study isolates one-session power.

Expert Insights on Mechanisms and Equality

Bettariga stated both modalities work equally well overall, with HIIT linking to body composition improvements like fat loss and muscle gain. ECU team noted workouts produced sufficient myokines to combat cancer. BreastCancer.org affirmed it boosts the body’s growth-slowing ability, validating post-treatment exercise. Authors speculate HIIT’s IL-6 peak reflects intensified stress, enhancing acute suppression.

Media slightly rounds reductions to 25%, while the study specifies precise ranges. In vitro limits apply—human recurrence trials remain needed—but rigor stands: randomized design, validated cells.